25.10.2012 • NewsAstraZenecaQ3 2012sales and profits

New CEO Has Work Cut Out as AstraZeneca Sales Fall

AstraZeneca's sales slumped 19% in the third quarter, underscoring the scale of the challenge confronting the drugmaker's new chief executive, Pascal Soriot.

Faced with patent expiries on once best-selling medicines and a thin pipeline of new drugs, the former Roche executive, who joined on Oct. 1, needs to re-focus operations and step up the hunt for acquisitions, analysts believe.

Sales in the quarter were $6.68 billion, generating "core" earnings, which exclude certain items, down 12% at $1.51 a share, AstraZeneca said on Thursday.

Industry analysts, on average, had forecast sales in the quarter of $6.75 billion and earnings of $1.44 a share, according to Thomson Reuters I/B/E/S.

AstraZeneca reiterated its forecast for a fall in full-year core earnings to between $6.00 and $6.30 a share, against $7.28 in 2011.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.